ADVERTISEMENT
News » Money
May 20, 5:06 PM EDT

Red Hat, JA Solar, Xenoport, Tellabs are big market movers on Monday

Business Video
Buy AP Photo Reprints
Interactives
Greece's Debt Threatens to Spread
State budget
gaps map
Auto industry problems trickle down, punish Tennessee county
Women give old Derby hats a makeover in tough economy
S.C. town deals with highest unemployment in South
How mortgages were bundled and sold as securities
Tracking the $700 billion financial bailout
Tracking the year's job losses
State-by-state foreclosures since 2007
Credit crisis explained
Presidents and their economic legacies
Lexicon of the financial crisis
Americans' addiction to debt
Interactive
Are Stocks Bouncing Back?

NEW YORK (AP) -- Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:

NYSE

Chesapeake Energy Corp., up 53 cents at $20.80

The natural gas company named Anadarko Petroleum Corp. executive Robert Douglas Lawler as its new chief executive officer.

Red Hat Inc., down $2.34 at $52.65

A BMO Capital Markets analyst downgraded the software company's shares after a big share-price increase in May.

WPX Energy Inc., down $1.30 at $19.76

Hedge fund Taconic Capital Advisors said in a regulatory filing that it now has a 6.39 percent interest in the oil and gas company.

Tellabs Inc., down 14 cents at $2.02

The communications equipment maker said that its chief financial officer is resigning for personal reasons.

Nasdaq

JA Solar Holdings Co. Ltd., up $3.95 at $9.56

The Chinese solar company said that its loss narrowed during its first quarter, helped by stronger-than-expected demand.

Warner Chilcott PLC, up 39 cents at $19.60

Actavis Inc. said that it is buying rival drugmaker Warner Chilcott in an all-stock transaction valued at about $8.5 billion.

Ironwood Pharmaceuticals Inc., down 56 cents at $13.83

A Cantor Fitzgerald analyst reiterated her "Sell" rating on the constipation treatment maker, citing a weak reception to its new drug.

Xenoport Inc., down $1.03 at $5.72

The drug developer said that a potential treatment for multiple sclerosis patients failed in late-stage clinical testing.

© 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. Learn more about our Privacy Policy and Terms of Use.

 
ADVERTISEMENT